Increased Risk of Diabetes after Definitive Radiotherapy in Patients with Indolent Gastroduodenal Lymphoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma. Materials and methods: This retrospective study included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region who were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution. Of total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (control group). A diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes event (DE) were defined as HbA1c level of ≥ 6.5%. Results: During the median follow-up of 49 months, no local failure occurred after RT and no patients died of lymphoma. The RT group had significantly higher risk for DAEs on univariable analysis (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.64 to 10.66; p < 0.01) and multivariable analysis (HR, 3.68; 95% CI, 1.42 to 9.56; p=0.01). Further, the DE risk was significantly higher in the RT group than in the control group (HR, 4.32; 95% CI, 1.08 to 17.30; p=0.04) and in patients with increased baseline HbA1c levels (HR, 35.83; 95% CI, 2.80 to 459.19; p=0.01). On multivariable analysis, RT significantly increased the risk of DEs (HR, 4.55; 95% CI, 1.08 to 19.19; p=0.04), even after adjusting baseline HbA1c level (HR, 40.97; 95% CI, 3.06 to 548.01; p=0.01). Conclusion: Patients who received RT for gastroduodenal indolent lymphoma had an increased risk of diabetes compared to those who did not.
Abstract
Purpose: This study aimed to evaluate the effect of radiotherapy (RT) on the risk of diabetes by assessing hemoglobin A1c (HbA1c) levels in patients with gastroduodenal indolent lymphoma. Materials and methods: This retrospective study included patients with stage I extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue or follicular lymphoma of the gastroduodenal region who were treated with Helicobacter pylori eradication and/or RT between 2000 and 2019 in our institution. Of total 79 patients with HbA1c test, 17 patients received RT (RT group), while 62 patients did not receive RT (control group). A diabetes-associated event (DAE) was defined as a ≥ 0.5% increase in HbA1c levels from baseline, and diabetes event (DE) were defined as HbA1c level of ≥ 6.5%. Results: During the median follow-up of 49 months, no local failure occurred after RT and no patients died of lymphoma. The RT group had significantly higher risk for DAEs on univariable analysis (hazard ratio [HR], 4.18; 95% confidence interval [CI], 1.64 to 10.66; p < 0.01) and multivariable analysis (HR, 3.68; 95% CI, 1.42 to 9.56; p=0.01). Further, the DE risk was significantly higher in the RT group than in the control group (HR, 4.32; 95% CI, 1.08 to 17.30; p=0.04) and in patients with increased baseline HbA1c levels (HR, 35.83; 95% CI, 2.80 to 459.19; p=0.01). On multivariable analysis, RT significantly increased the risk of DEs (HR, 4.55; 95% CI, 1.08 to 19.19; p=0.04), even after adjusting baseline HbA1c level (HR, 40.97; 95% CI, 3.06 to 548.01; p=0.01). Conclusion: Patients who received RT for gastroduodenal indolent lymphoma had an increased risk of diabetes compared to those who did not.
참고문헌 (25)
- Yahalom J, "Modern radiation therapy for extranodal lymphomas : field and dose guidelines from the International Lymphoma Radiation Oncology Group", Int J Radiat Oncol Biol Phys, 92, pp.11~31 (2015)
- Zelenetz AD, "NCCN guidelines insights: B-cell lymphomas, version 3.2019", J Natl Compr Canc Netw, 17, pp.650~661 (2019)
- Zucca E, "Marginal zone lymphomas : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 31, pp.17~29 (2020)
- Kim SW, "Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma", World J Gastroenterol, 19, pp.6062~6068 (2013)
- 이한상, "Radiation Therapy Outcome and Clinical Features of Duodenal-Type Follicular Lymphoma", Cancer Research and Treatment, 51(2), pp.547~555 (2019), 대한암학회
- Ruskone-Fourmestraux A, "Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma : Results of a prospective study with a long term follow-up", Radiother Oncol, 117, pp.178~182 (2015)
- Harada A, "Radiation therapy for localized duodenal low-grade follicular lymphoma", J Radiat Res, 57, pp.412~417 (2016)
- Pinnix CC, "Outcomes after reduced-dose intensity modulated radiation therapy for gastric mucosa-associated lymphoid tissue(MALT)lymphoma", Int J Radiat Oncol Biol Phys, 104, pp.447~455 (2019)
- American Diabetes Association, "2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2020", Diabetes Care, 43(Suppl 1), pp.S14~S31 (2020)
- Marks LB, "Use of normal tissue complication probability models in the clinic", Int J Radiat Oncol Biol Phys, 76(3 Suppl), pp.S10~S19 (2010)
- de Vathaire F, "Radiation dose to the pancreas and risk of diabetes mellitus in childhood cancer survivors : a retrospective cohort study", Lancet Oncol, 13, pp.1002~1010 (2012)
- Meacham LR, "Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study", Arch Intern Med, 169, pp.1381~1388 (2009)
- van Nimwegen FA, "Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma", J Clin Oncol, 32, pp.3257~3263 (2014)
- Groot HJ, "Risk of diabetes after para-aortic radiation for testicular cancer", Br J Cancer, 119, pp.901~907 (2018)
- Gemici C, "Risk of endocrine pancreatic insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer", Radiother Oncol, 107, pp.195~199 (2013)
- Sherwani SI, "Significance of HbA1c test in diagnosis and prognosis of diabetic patients", Biomark Insights, 11, pp.95~104 (2016)
- Abbas H, "Motion management in gastrointestinal cancers", J Gastrointest Oncol, 5, pp.223~235 (2014)
- Giraud P, "Respiratory gating for radiotherapy : main technical aspects and clinical benefits", Bull Cancer, 97, pp.847~856 (2010)
- Wagman R, "Respiratory gating for liver tumors : use in dose escalation", Int J Radiat Oncol Biol Phys, 55, pp.659~668 (2003)
- Petersen JB, "Normal liver tissue sparing by intensity-modulated proton stereotactic body radiotherapy for solitary liver tumours", Acta Oncol, 50, pp.823~828 (2011)
- Hoskin PJ, "4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma(FORT) : a randomised phase 3 non-inferiority trial", Lancet Oncol, 15, pp.457~463 (2014)
- Pinnix CC, "Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma", Head Neck, 39, pp.1095~1100 (2017)
- Girinsky T, "Low-dose radiation treatment in pulmonary mucosa-associated lymphoid tissue lymphoma : a plausible approach? A single-institution experience in 10 patients", Int J Radiat Oncol Biol Phys, 83, pp.e385~e389 (2012)
- Konig L, "Response rates and recurrence patterns after low-dose radiotherapy with 4Gy in patients with low-grade lymphomas", Strahlenther Onkol, 194, pp.454~461 (2018)
- Gunther JR, "Radiation therapy for salivary gland MALT lymphoma : ultra-low dose treatment achieves encouraging early outcomes and spares salivary function)", Leuk Lymphoma, 61, pp.171~175 (2020)